Last reviewed · How we verify
Ertugliflozin 5 mg (ertugliflozin-5-mg)
Ertugliflozin-5-mg is a medication developed by Pfizer Inc. for the treatment of type 2 diabetes. It works by inhibiting the SGLT2 protein, which is involved in glucose reabsorption in the kidneys. This leads to increased glucose excretion in the urine, resulting in improved glycemic control. Ertugliflozin has been shown to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. The drug has been commercially successful, generating $21.2B in revenue. It is marketed as a treatment adjunct to diet and exercise for adults with type 2 diabetes. Ertugliflozin has undergone extensive clinical trials, with 18 studies conducted and 39 publications.
At a glance
| Generic name | ertugliflozin-5-mg |
|---|---|
| Sponsor | Pfizer |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Treatment of type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Common side effects
- Upper respiratory tract infection
- Hypoglycaemia
- COVID-19
- Nasopharyngitis
- Headache
- Gastritis
- Pyrexia
- Influenza
- Gastroenteritis
- Nausea
- Abdominal pain
- Vomiting
Drug interactions
- Warfarin
- Insulin
- Pioglitazone
- Rosiglitazone
- Sulfonylureas
- Metformin
- SGLT2 inhibitors
- ACE inhibitors
- ARBs
- NSAIDs
- Diuretics
- Corticosteroids
Key clinical trials
- Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059) (PHASE3)
- Ertugliflozin to Reduce Arrhythmic Burden in ICD/CRT patientS (ERASe-Trial) - a Phase III Study (PHASE3)
- Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD (PHASE4)
- Ertugliflozin for Functional Mitral Regurgitation (PHASE3)
- Effect of Ertugliflozin on Cardiac Function in Diabetes (PHASE3)
- Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure (PHASE4)
- ERTU-SODIUM: Study on the Effects of Ertugliflozin on Sodium Storage, Interstitial Volume, and Plasma Volume in HFrEF (PHASE4)
- Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ertugliflozin 5 mg CI brief — competitive landscape report
- Ertugliflozin 5 mg updates RSS · CI watch RSS
- Pfizer portfolio CI